Motor Impact of Fasting in Parkinson’s Disease Patients: An overview
Objective: To provide a literature overview of fasting impact on motor symptoms in Parkinson disease. Background: Fasting, characterized by voluntary abstinence from food and caloric…Alpha-Synuclein and Mitochondria Quality Control in Parkinson’s Disease: A Literature Review
Objective: To provide an overview of the current knowledge on alpha-synuclein (αS) interactions with mitochondrial quality control (MQC) pathways in Parkinson’s disease (PD). Background: The…Harnessing chaperone-mediated autophagy through viral-based LAMP2A overexpression in non-human primates as a Treatment of Parkinson’s Disease
Objective: This project aimed to investigate whether the CMA lysosomal pathway induction may benefit the highest-order mammalian synucleinopathy model, the non-human primate, by targeting CMA’s…Safety and Efficacy of the Anti-alpha Synuclein Monoclonal Antibody Lu AF82422 for the Treatment of Patients with MSA: Results from the Phase 2 AMULET Trial
Objective: Assess the efficacy and safety of monthly IV infusions with the anti-alpha synuclein [a-syn] monoclonal antibody Lu AF82422 for the treatment of patients with…Clinical Utility of Synuclein Skin Biopsy in the Initial Diagnosis and Evaluation of Parkinsonian Disorders
Objective: To determine the clinical utility of phosphorylated alpha-synuclein (P-SYN) within skin biopsies in diagnostic and management decisions. Background: The initial diagnosis of Parkinson’s Disease…The Purely Thermodynamic Anti-prionic Mode of Action for the Treatment of Parkinson’s Disease and other Neurodegenerative Diseases
Objective: Demonstration of the anti-prionic MoA for α-synuclein in vitro, PoC in vivo, as well as ex vivo. Background: Neurodegenerative protein-misfolding diseases, like Alzheimer’s (AD)…Discriminating alpha-synuclein strains in Parkinson’s disease
Objective: To evaluate possible differences in the biological properties of alpha-synuclein fibrils derived from different patients with Parkinson's disease. Background: Parkinson’s disease (PD) is a…V-ATPase subunit V1G1 overexpression conferred the mice neuroprotection during MPTP exposure
Objective: Elucidating the role of lysosomal dysfunction due to altered stability and expression levels of V-type proton ATPase subunit G (V1G1) in the degradation and…Seed Amplification Assay for the differentiation of αSyn seed subtypes
Objective: To identify soluble αSyn-seed types present in brain homogenate (BH) and CSF using αSyn seed amplification assay (synSAA) Background: Lewy bodies and neurites are…Real-world use of biomarkers for Parkinsonism: Should I do this (pSyn) or DaT?
Objective: To examine the utility of commercially available skin phosphorylated alpha-synuclein deposition test (pSyn) in patients with clinically ambiguous parkinsonism and its concordance with dopamine…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 60
- Next Page »